Science Today

The real mind which influenced me to rethink about Pharmacy as a career option and as a professional opportunity. @Zeenatiqbal11 pic.twitter.com/kpY8BhJqH1 — M. Mirza Riyaz Beig (@1996Mirza) October 26, 2019 Race With Dreams! © 2015-2016

B. Pharm, S.P.E.R, Jamia Hamdard, New Delhi Race With Dreams! © 2015-2016 Officials with the FDA have approved lasmiditan (Reyvow, Eli Lilly) tablets for the acute treatment of migraine with or without aura in adults, according to the agency. Migraines can cause debilitating symptoms, such as intense throbbing or pulsing pain in 1 area of the head, nausea and/or vomiting, and sensitivity to light and sound. Approximately one-third of individuals who suffer from migraine also experience aura, which can appear as flashing lights, zig-zag lines, or a temporary loss of vision shortly before the migraine occurs. Lasmiditan is an oral, centrally-penetrant, selective serotonin 5-HT1F agonist that is structurally and mechanistically distinct from other approved migraine therapies, according to Lilly. Unlike other therapies on the market, lasmiditan has been designed to treat migraines without vasoconstrictor activity, according to a press release. Upon submission of lasmiditan’s new drug app...